Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews alopecia areata treatments, noting varied outcomes, and reports no new clinical results.

This study aims to evaluate the effectiveness of YH0618 granules in preventing chemotherapy-induced hair loss in breast cancer patients through a randomized, double-blind, multi-center clinical trial, focusing on potential mechanisms related to kidney deficiency as understood in Chinese Medicine. Results are not yet reported.

Congenital triangular alopecia can occur outside the typical fronto-temporal region.

This study found that intralesional triamcinolone acetonide was more effective than saline for hair regrowth in scalp alopecia areata, with 10 mg/mL showing the best response but more side effects.

In this study, researchers found that triamcinolone acetonide provided earlier visual improvement in alopecia areata treatment, but by 12 weeks, both triamcinolone acetonide and betamethasone 1.75 mg/ml showed similar effectiveness compared to lower-dose betamethasone and placebo.

This study at Abbasi Shaheed Hospital reported that intralesional triamcinolone acetonide via Dermojet was highly effective, with 75 out of 100 alopecia areata patients showing significant hair regrowth in affected patches.

In this study, 70 patients with alopecia areata who received intralesional triamcinolone showed a significant reduction in black dots, yellow dots, broken hair, and tapering hair, while achieving a 60% success rate in hair regrowth.

This case series reported incidents of iatrogenic Cushing's Syndrome linked to high doses of intralesional corticosteroid injections and mesotherapy regimens, highlighting the need for cautious prescription practices and further research on mesotherapy safety.

This review discusses the potential role of a PADI3 gene variant in central centrifugal cicatricial alopecia among African-American women but reports no new clinical results.

This study found that combining 308-excimer phototherapy with intramuscular triamcinolone acetonide was effective and well tolerated for treating resistant alopecia totalis, showing a 90% overall response rate in the ten patients studied, with the best results observed in younger patients.

This case report highlights a rare instance of permanent hair loss caused by an allergic reaction to a mesotherapy mixture containing triamcinolone acetonide, suggesting that hypersensitivity reactions to such mixtures are possible.

This article discusses triangular temporal alopecia, highlighting dermoscopy's role in diagnosis and the limited therapeutic options, without reporting new clinical results.

Injecting triamcinolone into the eyebrow area may help eyelash regrowth in alopecia areata patients.

This study found no significant difference in the therapeutic response to intralesional triamcinolone acetonide at concentrations of 2.5, 5, and 10 mg/mL for various dermatologic conditions.

This study found that intralesional vitamin D3 achieved similar effectiveness to triamcinolone acetonide for treating patchy alopecia areata but was associated with fewer adverse effects and higher patient satisfaction.

This study found that treating patchy alopecia areata with fractional CO2 laser and topical triamcinolone acetonide was more effective and safer than intralesional triamcinolone, despite higher initial discomfort, as it resulted in greater patient satisfaction and fewer adverse effects like skin atrophy.

This study reported that while Intralesional Triamcinolone Acetonide injections effectively improved mouth opening in patients with Oral Submucous Fibrosis, it also led to symptoms of Cushing's Syndrome, highlighting the need for careful monitoring of adverse effects.

This case report describes a 29-year-old man who developed scalp abscesses due to Mycobacterium abscessus infection after receiving scalp injections for hair loss, successfully treated with antibiotics.

This study found that intralesional triamcinolone acetonide at both 5 mg/mL and 10 mg/mL concentrations had similar effectiveness and safety for treating patchy alopecia areata on the scalp, with no significant difference in response rates or side effects between the two dosage groups.

This study identified a new minoxidil analogue called triaminodil in an illegal hair-growth supplement, but no data on its chemical, toxicological, or pharmacological properties are available yet.

This case report documents a rare instance of triangular temporal alopecia in an adult woman, emphasizing the importance of correct diagnosis to avoid unnecessary treatments, and reviews the literature on TTA.

This study suggests that peri-incisional triamcinolone acetonide may subtly benefit wound edge apposition in low-tension scalp regions during hair restoration surgery, but shows no statistically significant overall effect.

This study found that hair growth was maintained in alopecic sites using scalp autografts with triamcinolone acetonide, but homografts were typically rejected.

In this case report, a 35-year-old man developed avascular necrosis after receiving intradermal corticosteroid injections for alopecia areata, marking the first documented instance of this side effect from such treatment.

This study found that platelet-rich plasma showed similar efficacy to intralesional triamcinolone acetonide for treating mild patch-type alopecia areata, offering a potential alternative with fewer steroid-related side effects.

This study found that while both microneedling-assisted methotrexate and triamcinolone acetonide treatments led to improvements in recalcitrant alopecia areata, methotrexate-treated areas had significantly better outcomes in terms of SALT score reduction, patient satisfaction, and relapse rates, suggesting its superior short-term efficacy.

This study found that radiofrequency microneedling significantly enhanced the absorption of topical triamcinolone acetonide, with insertion depth being more influential than RF energy levels.

This study developed a new triamcinolone acetonide serum combined with a microneedling device, showing promise for treating alopecia areata by targeting hair follicles in a less invasive, patient-friendly way with confirmed drug solubility, compatibility, and safety.

This study developed a low-viscosity triamcinolone acetonide serum, used with a derma stamp microneedling device, to improve targeted treatment of alopecia areata, reporting favorable drug solubility, spreadability, and permeation to hair follicles, while maintaining skin safety.

This study concluded that platelet-rich plasma therapy was as effective as intralesional triamcinolone acetonide in treating localized alopecia areata on the scalp.